Kidney disease treatment is undergoing a transformation, driven by exciting new research that reveals the protective power of semaglutide in patients with type 2 diabetes. Semaglutide, a medication ...

IgA nephropathy is a progressive disease where immune proteins damage the kidneys' filtering units. Treatment options include medications and lifestyle changes to help slow progression and manage ...

R1 Therapeutics is debuting with an oversubscribed $77.5 million series A financing aimed at advancing its first-in-class ...

IgA nephropathy (IgAN) is a kidney condition where antibodies (immune system proteins) build up and cause damage in your kidneys. IgAN, also known as Berger's disease, does not have a cure. However, ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Currently, several phase two and phase ...

Dr Suneel Udani describes an impactful case that illustrates how the treatment landscape for IgA nephropathy is changing: a young mother referred with high proteinuria and worrying changes in kidney ...

IgA nephropathy, an immune assault on the kidneys, is often missed. New treatments mean that spotting it sooner might save ...

The FDA granted accelerated approval to sibeprenlimab injection (Voyxact) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy at risk for disease progression, ...

The NefIgARD open-label extension demonstrated that extending the course or retreating patients with targeted-release formulation (TRF)-budesonide is safe and effective in the treatment of ...

Renalys Pharma is vying for the approval of its in-licensed immunoglobulin A (IgA) nephropathy asset, Filspari (sparsentan) in Japan, following the positive results of a Phase III trial. During the ...

Panelists discuss how the management of immunoglobulin A (IgA) nephropathy is undergoing a transformative shift from symptom control to targeted disease modification, with emerging therapies offering ...

The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the ...